NCT00172380View on ClinicalTrials.gov

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

March 31, 2010

Conditions
NSCLC
Interventions
DRUG

Docetaxel Plus CDDP

docetaxel 36mg/m2 and cisplatin 75mg/m2

Trial Locations (1)

100

Department of Internal Medicine, National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT00172380 - Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III | Biotech Hunter | Biotech Hunter